---
title: "Baxter: Turnaround Progress but Muted 2026 Outlook Keeps Hold Rating and $22 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284277448.md"
description: "Baxter International's stock rating remains a Hold with a $22 price target, according to analyst Josh Jennings from TD Cowen. He cites confidence in the company's new leadership and initiatives to improve operations, but notes a muted outlook for 2026 with stagnant revenue and declining EPS. Jennings expects quarterly results to align with management's guidance, with limited near-term catalysts for stock performance due to known headwinds in key segments. Overall, he maintains a neutral stance on the stock."
datetime: "2026-04-27T22:45:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284277448.md)
  - [en](https://longbridge.com/en/news/284277448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284277448.md)
---

# Baxter: Turnaround Progress but Muted 2026 Outlook Keeps Hold Rating and $22 Price Target Unchanged

Baxter International, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen reiterated a Hold rating on the stock and has a $22.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Josh Jennings has given his Hold rating due to a combination of factors, including confidence that Baxter’s new leadership and GPS initiative can gradually enhance operational performance while the shares still trade below peer valuations. At the same time, he believes the turnaround will take time, and the muted 2026 outlook—with stagnant organic revenue and a notable EPS decline—limits the near-term case for upgrading the stock, so the price target remains unchanged at $22.

Jennings also anticipates that upcoming quarterly results will broadly track management’s guidance and consensus expectations, with a particularly tough first quarter followed by gradual improvement as the year progresses. Given that segment-specific headwinds in Infusion Therapies, Healthcare Systems & Technologies, and Pharma are largely known and expected to ease in the second half, he sees limited catalysts for outperformance in the near term, which supports maintaining a neutral stance rather than turning more bullish.

### Related Stocks

- [BAX.US](https://longbridge.com/en/quote/BAX.US.md)

## Related News & Research

- [Baxter’s Post-Divestiture Profit Focus Might Change The Case For Investing In Baxter International (BAX)](https://longbridge.com/en/news/289972928.md)
- [Intel Stock Is Soaring: Why a $150 Price Target Could Be Within Reach in 2026](https://longbridge.com/en/news/290215494.md)
- [12:03 ETAutomating Infusion Care: Eitan Medical and WeInfuse Deliver Seamless Pump-to-Workflow Integration](https://longbridge.com/en/news/289944997.md)
- [KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update](https://longbridge.com/en/news/289690506.md)
- [Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia](https://longbridge.com/en/news/289697616.md)